Clinical Trial Search

Primary: Number of Participants With Clinically Significant CMV Reactivation or CMV Disease — 62; 89; 78; 32 Participants

Primary: Proportion of Patients Developing Cytomegalovirus (CMV) Disease Within 6 Months of Liver Transplantation Under Valcyte Prophylaxis — 3 participants

Primary: Number of Patients With Late CMV Disease — 0; 0 Participants

Primary: Area Under the Curve (AUC) — 21.0 mcg∙h/mL

Primary: Number of Participants With Adverse Events (AE), Serious Adverse Events (SAE) or Withdrawal Due to AEs — 56; 41; 6 Participants

Primary: Time to Engraftment (Days) Stratified by CMV DNaemia Occurring Before or After Neutrophil's Engraftment — 17; 19 days

Primary: Incidence of Cytomegalovirus (CMV) Disease. — 9; 20 participants — p=0.0396

Primary: Incidence of CMV Disease or CMV Viremia — 29; 9; 26 Participants

Primary: Number of Participants With Endpoint Committee (EC)-Confirmed Cytomegalovirus (CMV) Disease Within 6 Months Post-Transplantation — 14; 10 number of participants with…

Primary: Percentage of Participants With Clinically Significant Cytomegalovirus (CMV) Infection up to Week 24 Post-Transplant — 32 Percentage of Participants

Primary: Number of Participants With a Complete Response — 8; 50 Participants

Primary: Proportion of Patients With Neutropenia Compared to Historical Controls — 0; 30 Participants — p=0.02

Primary: Incidence of CMV End Organ Disease — 21; 1 participants

Primary: Compare Incidence, Duration and Magnitude of CMV and EBV Viremia in Kidney Transplant Recipients Receiving valA vs. valG. — 16; 20; 8; 4 Participants

Primary: Number of Participants With Clinically Significant CMV Infection — 13; 4; 6; 4 Participants

Primary: Incidence of EBV or CMV Related Disease in Transplant Recipient — 2; 0 participants

Primary: Number of Participants With Adverse Events and Serious Adverse Events — 6; 3; 23; 12 Participants

Primary: Percentage of Participants With Active Cytomegalovirus (CMV) Infection Within 12 Months — 14.1; 42.6 percentage of participants

Primary: Percentage of Participants With Adverse Events (AEs) — 90.9 Percentage of Participants

Primary: Clinically Significant CMV Viremia for Hematopoietic Cell Transplantation/HCT Participants in the Interventional Cohort Only — 5; 0; 31; 0 Participants

Primary: Number of Participants With Clinically Significant CMV Infection Through Week 24 Post-Transplant — 155; 78 Participants

Primary: Number of Participants With Non-Relapse Mortality — 0 Participants

Primary: Number of Ears That Had (1) Improved Hearing or no Change in Hearing (2) Worsened Hearing. — 27; 20; 1; 6 Ears — p=0.0859

Primary: Number of Subjects With Any Cytomegalovirus (CMV) Congenital Infection — 24; 20; 4; 58 Participants

Primary: Percentage of Patients Who Developed Cytomegalovirus (CMV) Disease up to Month 12 Post-transplant — 43.6; 23.9 Percentage of patients — p=<=0.0002

Primary: Number of Participants With at Least One Biopsy Proven Acute Rejection (BPAR) Episode, Graft Loss or Death Within the First Three Months Post-transplantation — 8; 15…

Primary: Complete Response — 20; 57 Participants

Primary: Clinical Significant Leukopenia — 8; 1 Participants

Primary: Number of Participants Sustained Virological Response (SVR) Following Treatment of Hepatitis C Virus (HCV) Infection With Peg-IFN and Ribavirin in Liver Transplanted…

Primary: Incidence of Post Transplant Lymphoproliferative Disorder (PTLD) — 6 participants